Publications by authors named "Carmen Rodriguez-Tenreiro-Sanchez"
Article Synopsis
- Galicia, Spain, launched a program in September 2023 to give nirsevimab for RSV prevention in infants, focusing on newborns, those under 6 months, and high-risk children aged 6-24 months.
- The interim analysis of the study, using data from Sept 25 to Dec 31, 2023, assesses nirsevimab's effectiveness in preventing different levels of RSV-related hospitalizations and complications.
- The study compares the results with data from previous RSV seasons to calculate how many cases of hospitalization were potentially avoided due to the immunization campaign.
Background: Studies on vaccine effectiveness (VE) against COVID-19 in the pediatric population are outgoing. We aimed to quantify VE against SARS-CoV-2 in two pediatric age groups, 5-11 and 12-17-year-old, while considering vaccine type, SARS-CoV-2 variant, and duration of protection.
Methods: A population-based test-negative control study was undertaken in Galicia, Spain.
Background: Both pathogenic bacteria and viruses are frequently detected in the nasopharynx (NP) of children in the absence of acute respiratory infection (ARI) symptoms. The aim of this study was to estimate the aetiological fractions for ARI hospitalisation in children for respiratory syncytial virus (RSV) and influenza virus and to determine whether detection of specific respiratory pathogens on NP samples was associated with ARI hospitalisation.
Methods: 349 children up to 5 years of age hospitalised for ARI (following a symptom-based case definition) and 306 hospital controls were prospectively enrolled in 16 centres across seven European Union countries between 2016 and 2019.
Objective: The health crisis caused by COVID-19 required the prompt launch of research in order to generate scientific evidence pertaining to the new disease oriented to control its devastating effects and continuous spread. Therefore, it was essential to adapt the work flow of Research Ethics Committees, to prioritize and to accelerate the evaluation of projects related to this disease.
Methods: This work analyses the evaluation conducted by our Regional Ethics Committees during the initial period of the health emergency (between 13th March and 28th May 2020).
Article Synopsis
- Respiratory syncytial virus (RSV) significantly impacts healthy infants, leading to many hospitalizations worldwide, and understanding its burden in Europe is critical for future vaccine and treatment development.
- A study will follow 10,000 healthy infants over three years to track RSV-related hospitalizations through questionnaires and medical records, focusing on a smaller group of 1,000 for detailed respiratory sampling.
- The main goal is to gather data on the rate of RSV-related hospitalizations and respiratory infections in infants, which will enhance knowledge on RSV's impact and aid healthcare strategies.
Unlabelled: Respiratory syncytial virus (RSV) is the leading viral pathogen associated with acute lower respiratory tract infection and hospitalization in children < 5 years of age worldwide. While there are known clinical risk factors for severe RSV infection, the majority of those hospitalized are previously healthy infants. There is consequently an unmet need to identify biomarkers that predict host response, disease severity, and sequelae.
View Article and Find Full Text PDFArticle Synopsis
- Respiratory syncytial virus (RSV) is a leading cause of hospitalization in infants, and swift detection is crucial for effective treatment and reducing unnecessary antibiotic use.
- The BinaxNOW RSV (BN) test was assessed for its accuracy in diagnosing RSV compared to molecular testing, evaluating samples from 148 children with varying respiratory illness severity.
- The study showed that BN had a low sensitivity of 7.6% but a high specificity of 100%, indicating it may not be reliable for RSV detection in clinical settings and should be used cautiously.
With the increase in the number of routine vaccinations the development of pentavalent and hexavalent combination vaccines fitting the routine vaccination schedules became a necessity. In this respect, Europe has taken the lead in comparison with other world regions, and routine vaccination with pentavalent and hexavalent combinations including DTPa, Hib, HepB and IPV has been on European vaccination programs for >15years. Since the marketing authorization of Hexavac® and Infanrix Hexa® in 2000, immunization schedules in most European countries have included hexavalent vaccines.
View Article and Find Full Text PDFN. meningitidis is a major cause of meningitis and septicemia and a major public health problem in many countries. The disease, that can be fulminant, has a high mortality and may cause serious sequelae, even in cases of apparently optimal medical treatment.
View Article and Find Full Text PDF